Dive Insight: Merck KGaA’s proposed acquisition of SpringWorks is the first biotech buyout worth more than $1 billion to be announced since mid-January, when Johnson & Johnson agreed to purchase ...

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) is up 47.80% year-to-date. Overall, SWTX ranks 14th on our list of the biotech stocks that are skyrocketing so far in 2025.

Revenue Growth: SpringWorks Therapeutics's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 1029.96%.

As the FDA mulls over SpringWorks’ experimental neurofibromatosis type 1 plexiform neurofibromas (NF1-PN) drug mirdametinib during its rolling submission, the biotech isn't wasting time in ...

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) is a commercial-stage biopharmaceutical company focusing on cancer and severe rare diseases. OGSIVEO (nirogacestat) is its FDA-approved therapy for ...

SpringWorks Therapeutics' cash burn of US$67m is about 1.8% of its US$3.7b market capitalisation. That means it could easily issue a few shares to fund more growth, and might well be in a position ...

SpringWorks Therapeutics is launching a new disease state education campaign at DesmoidTumors.com. The clinical-stage biotech, which is working on medicines to help patients suffering from rare ...

SpringWorks is using Nirogacestat, while AbbVie provides ABBV-383. It is believed that Nirogacestat provides a boost for BCMA therapies like ABBV-383. This isn't the first partnership for SpringWorks.

Conclusion As I write on 08/07/2024 SpringWorks is trading at a market cap of ~$2.46 billion. SpringWorks presents an interesting acquisition opportunity for investors with a high-risk tolerance.

SpringWorks Therapeutics Inc has a consensus price target of $55 based on the ratings of 9 analysts. The high is $77 issued by Wedbush on February 12, 2025.

SpringWorks Therapeutics is planning to initiate a Phase 3 program to establish safety and efficacy of its MEK 1/2 inhibitor (PD-0325901) in the NF1 population and will work collaboratively with ...

Merck KGaA’s proposed acquisition of SpringWorks is the first biotech buyout worth more than $1 billion to be announced since mid-January, when Johnson & Johnson agreed to purchase Intra ...